Profile
| Metric | Value |
|---|---|
| Full Name | Repligen Corporation |
| Ticker | NASDAQ: RGEN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | repligen.com |
| Employees | 1,778 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $166.42 | |
| Price, 1D Change | -1.56% | |
| Market Cap | $9B | |
| - | ||
| PE Ratio | 6,450.39 | |
| Beta | 1.43 | |
| Revenue | $634M | |
| Revenue, 1Y Change | +0.33% | |
| EPS | -$0.46 | |
| EPS, 1Y Change | -172.24% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.46 | |
| EPS Estimate | $1.67 | |
| EPS Est. Change | +465.71% | |
| Revenue | $634.44M | |
| Revenue Estimate | $733.13M | |
| Revenue Est. Change | +15.56% | |
| Current Price | $166.42 | |
| Price Target | - | $190.00 |
| Price Tgt. Change | - | +14.17% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.73 | $0.63 | -63.50% | |
| $1.53 | -$0.46 | -129.72% | |
| $1.67 | N/A | +465.71% | |
| $2.08 | N/A | +556.68% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $638.44M | $632.36M | -0.95% | |
| $634.06M | $634.44M | +0.06% | |
| $733.13M | N/A | +15.56% | |
| $824.39M | N/A | +29.94% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +7.58% | |
| Price, 3Y | +7.88% | |
| Market Cap, 1Y | +7.96% | |
| Market Cap, 3Y | +9.31% | |
| Revenue, 1Y | +0.33% | |
| Revenue, 3Y | -5.38% | |
| EPS, 1Y | -172.24% | |
| EPS, 3Y | -120.36% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $166.42 | |
| SMA 200 | $135.93 | |
| SMA 200 vs Price | -18.32% | |
| SMA 50 | $159.29 | |
| SMA 50 vs Price | -4.28% | |
| Beta | 1.43 | |
| ATR | $5.30 | |
| 14-Day RSI | 58.74 | |
| 10-Day Volatility | 23.06% | |
| 1-Year Volatility | 50.52% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $634.44M | |
| EPS | -$0.46 | |
| Gross Profit | $274.65M | |
| Gross Margin | 44.76% | |
| Operating Profit | -$31.92M | |
| Operating Margin | 3.57% | |
| Net Income | -$25.51M | |
| Net Margin | -4.02% | |
| EBITDA | -$6.30M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.27 | |
| Current Ratio | 8.41 | |
| Quick Ratio | 7.28 | |
| - | ||
| F-Score | 6 | |
| Altman Z-Score | 7.38 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 6,450.39 | |
| PS Ratio | 13.23 | |
| PB Ratio | 4.50 | |
| EV/EBITDA | 58.84 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.97B | |
| Cash & Equivalents | $757.36M | |
| Total Assets | $2.83B | |
| Current Assets | $1.07B | |
| Total Liabilities | $856.95M | |
| Current Liabilities | $126.79M | |
| Total Debt | $686.25M | |
| Short Term Debt | $15.10M | |
| Accounts Payable | $32.13M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $666.36M | |
| Operating Expenses | $306.57M | |
| Cost Of Goods Sold | $359.79M | |
| SG&A | $263.37M | |
| D&A | $86.56M | |
| Interest Expense | $0.00 | |
| Income Tax | -$1.52M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $175.39M | |
| CFI | -$86.38M | |
| CFF | -$82.90M | |
| Capex | $32.91M | |
| Free Cash Flow | $142.49M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Barclays | → | |
| Canaccord Genuity | → | |
| Barclays | → | |
| Evercore ISI Group | → | |
| Barclays | → | |
| HSBC | ||
| Evercore ISI Group | → | |
| Jefferies | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with RGEN
Data Sources & References
- RGEN Official Website www.repligen.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/730272/000119312525252385/0001193125-25-252385-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/730272/000095017025038999/0000950170-25-038999-index.htm
- RGEN Profile on Yahoo Finance finance.yahoo.com/quote/RGEN
- RGEN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rgen
FAQ
What is the ticker symbol for Repligen Corporation?
The ticker symbol for Repligen Corporation is NASDAQ:RGEN
Does Repligen Corporation pay dividends?
No, Repligen Corporation does not pay dividends
What sector is Repligen Corporation in?
Repligen Corporation is in the Healthcare sector
What industry is Repligen Corporation in?
Repligen Corporation is in the Medical Instruments & Supplies industry
What country is Repligen Corporation based in?
Repligen Corporation is headquartered in United States
When did Repligen Corporation go public?
Repligen Corporation initial public offering (IPO) was on April 29, 1986
Is Repligen Corporation in the S&P 500?
No, Repligen Corporation is not included in the S&P 500 index
Is Repligen Corporation in the NASDAQ 100?
No, Repligen Corporation is not included in the NASDAQ 100 index
Is Repligen Corporation in the Dow Jones?
No, Repligen Corporation is not included in the Dow Jones index
When was Repligen Corporation last earnings report?
Repligen Corporation's most recent earnings report was on October 28, 2025
When does Repligen Corporation report earnings?
The next expected earnings date for Repligen Corporation is February 17, 2026